Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review-Reference-Cited by-同舟云学术

Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review

Published:2016-08-24 Issue:12 Volume:12 Page:1433-1444
ISSN:1742-5255
Container-title:Expert Opinion on Drug Metabolism & Toxicology
language:en
Short-container-title:Expert Opinion on Drug Metabolism & Toxicology

Author:

Boudou-Rouquette Pascaline¹,Tlemsani Camille¹,Blanchet Benoit¹,Huillard Olivier¹,Jouinot Anne¹,Arrondeau Jennifer¹,Thomas-Schoemann Audrey¹²,Vidal Michel¹²,Alexandre Jérôme¹,Goldwasser François¹

Affiliation:

1. Department of Medical Oncology, CERIA, Paris Descartes University, AP-HP, Cochin Hospital, Paris, France

2. UMR8638 CNRS, UFR de Pharmacie, Université Paris Descartes, PRES Sorbonne Paris Cité, Paris, France

Publisher

Informa UK Limited

Subject

Pharmacology,Toxicology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17425255.2016.1225038

Reference97 articles.

1. Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

2. The VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk

3. Angiogenic Profile of Soft Tissue Sarcomas Based on Analysis of Circulating Factors and Microarray Gene Expression

4. Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study

5. A Three-Gene Signature for Outcome in Soft Tissue Sarcoma

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel VEGFR2 inhibitors with thiazoloquinoxaline scaffold targeting hepatocellular carcinoma with lower cardiotoxic impact;Scientific Reports;2023-08-25

2. Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ);Journal of Cancer Research and Clinical Oncology;2023-03-31

3. Prediction for optimal dosage of pazopanib under various clinical situations using physiologically based pharmacokinetic modeling;Frontiers in Pharmacology;2022-09-12

4. Dangerous interaction of bitter melon (Momordica charantia) with pazopanib: A case of acute pancreatitis;Journal of Oncology Pharmacy Practice;2021-09-27

5. Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma;Current Medicinal Chemistry;2021-05-31